On Oct 31, major Wall Street analysts update their ratings for $Biomea Fusion (BMEA.US)$, with price targets ranging from $19 to $60.
Oppenheimer analyst Matthew Biegler maintains with a buy rating, and maintains the target price at $60.
Piper Sandler analyst Joseph Catanzaro maintains with a buy rating, and adjusts the target price from $10 to $19.
Truist Financial analyst Srikripa Devarakonda upgrades to a buy rating.
H.C. Wainwright analyst Joseph Pantginis maintains with a buy rating, and maintains the target price at $40.
Furthermore, according to the comprehensive report, the opinions of $Biomea Fusion (BMEA.US)$'s main analysts recently are as follows:
Biomea Fusion is on course to present Phase 2 data for both type 1 and type 2 diabetes in December, indicating a notable progress post the Q3 report.
Here are the latest investment ratings and price targets for $Biomea Fusion (BMEA.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
